Actively Recruiting
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-05-14
200
Participants Needed
15
Research Sites
120 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy, LBL-024 in combination with LBL-007 or toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.
CONDITIONS
Official Title
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to follow the study treatment plan, visit schedule, laboratory tests, and other protocol requirements, and provide written informed consent
- Age 18 years or older at the time of signing informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected survival time of at least 12 weeks
- Have at least one measurable tumor lesion according to RECIST 1.1 criteria
- Male participants of childbearing potential and female participants of childbearing age agree to use highly effective contraception from consent signing until 6 months after the last trial drug administration
You will not qualify if you...
- Received live vaccination within 4 weeks before the first dose or planned to receive live vaccination during the study and for 4 weeks after dosing
- Underwent major surgery or significant treatment or diagnosis within 4 weeks before the first dose
- Have active autoimmune diseases or have a history with possible recurrence
- History of severe cardiovascular or cerebrovascular disorders
- Have an active infectious disease
- History of mental illness interfering with consent, drug abuse, alcoholism, or drug addiction
- Women who are pregnant or breastfeeding
- Other conditions deemed by the investigator to affect compliance or suitability for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
2
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
3
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510080
Not Yet Recruiting
4
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530200
Actively Recruiting
5
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
Actively Recruiting
6
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China, 210009
Actively Recruiting
7
The First Hospital of Jilin University
Changchun, Jilin, China, 130021
Not Yet Recruiting
8
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
9
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Not Yet Recruiting
10
Shanxi Bethune Hospital
Taiyuan, Shanxi, China, 030032
Actively Recruiting
11
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China, 710004
Not Yet Recruiting
12
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
13
Tianjin Medical University Cancer Institute &Hospital
Tianjin, Tianjin Municipality, China, 300060
Not Yet Recruiting
14
Yunnan Cancer Hospital
Kunming, Yunnan, China, 650118
Actively Recruiting
15
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Not Yet Recruiting
Research Team
Y
Yu Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here